180 related articles for article (PubMed ID: 6628930)
1. Quantitative fecal indium 111-labeled leukocyte excretion in the assessment of disease in Crohn's disease.
Saverymuttu SH; Peters AM; Lavender JP; Pepys MB; Hodgson HJ; Chadwick VS
Gastroenterology; 1983 Dec; 85(6):1333-9. PubMed ID: 6628930
[TBL] [Abstract][Full Text] [Related]
2. Correlation between levels of C-reactive protein and clinical activity in Crohn's disease.
Karoui S; Ouerdiane S; Serghini M; Jomni T; Kallel L; Fekih M; Boubaker J; Filali A
Dig Liver Dis; 2007 Nov; 39(11):1006-10. PubMed ID: 17889628
[TBL] [Abstract][Full Text] [Related]
3. Laboratory markers predict bone loss in Crohn's disease: relationship to blood mononuclear cell function and nutritional status.
Trebble TM; Wootton SA; Stroud MA; Mullee MA; Calder PC; Fine DR; Moniz C; Arden NK
Aliment Pharmacol Ther; 2004 May; 19(10):1063-71. PubMed ID: 15142195
[TBL] [Abstract][Full Text] [Related]
4. Urinary excretion of N-methylhistamine as a marker of disease activity in inflammatory bowel disease.
Winterkamp S; Weidenhiller M; Otte P; Stolper J; Schwab D; Hahn EG; Raithel M
Am J Gastroenterol; 2002 Dec; 97(12):3071-7. PubMed ID: 12492192
[TBL] [Abstract][Full Text] [Related]
5. [Alpha 1-antitrypsin and the percentage of fecal excretion of 111In-oxin-labeled leukocytes in Crohn disease].
Fischbach W; Becker W
Dtsch Med Wochenschr; 1985 Aug; 110(31-32):1233. PubMed ID: 3874762
[No Abstract] [Full Text] [Related]
6. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease.
Jones J; Loftus EV; Panaccione R; Chen LS; Peterson S; McConnell J; Baudhuin L; Hanson K; Feagan BG; Harmsen SW; Zinsmeister AR; Helou E; Sandborn WJ
Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1218-24. PubMed ID: 18799360
[TBL] [Abstract][Full Text] [Related]
7. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
[TBL] [Abstract][Full Text] [Related]
8. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
[TBL] [Abstract][Full Text] [Related]
9. Fecal lactoferrin and calprotectin after ileocolonic resection for Crohn's disease.
Scarpa M; D'Incà R; Basso D; Ruffolo C; Polese L; Bertin E; Luise A; Frego M; Plebani M; Sturniolo GC; D'Amico DF; Angriman I
Dis Colon Rectum; 2007 Jun; 50(6):861-9. PubMed ID: 17473939
[TBL] [Abstract][Full Text] [Related]
10. Clinical relevance of activity parameters in Crohn's disease estimated by the faecal excretion of 111In-labeled granulocytes.
Fischbach W; Becker W
Digestion; 1991; 50(3-4):149-52. PubMed ID: 1812041
[TBL] [Abstract][Full Text] [Related]
11. Assessment of disease activity in ulcerative colitis using indium-111-labelled leukocyte faecal excretion.
Saverymuttu SH; Peters AM; Hodgson HJ; Chadwick VS
Scand J Gastroenterol; 1983 Oct; 18(7):907-12. PubMed ID: 6676924
[TBL] [Abstract][Full Text] [Related]
12. Clinical remission in Crohn's disease--assessment using faecal 111In granulocyte excretion.
Saverymuttu SH
Digestion; 1986; 33(2):74-9. PubMed ID: 3949092
[TBL] [Abstract][Full Text] [Related]
13. Indium 111-granulocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel disease. A comparison with colonoscopy, histology, and fecal indium 111-granulocyte excretion.
Saverymuttu SH; Camilleri M; Rees H; Lavender JP; Hodgson HJ; Chadwick VS
Gastroenterology; 1986 May; 90(5 Pt 1):1121-8. PubMed ID: 3956932
[TBL] [Abstract][Full Text] [Related]
14. Indium-111-labeled autologous leukocyte imaging and fecal excretion. Comparison with conventional methods of assessment of inflammatory bowel disease.
Leddin DJ; Paterson WG; DaCosta LR; Dinda PK; Depew WT; Markotich J; McKaigney JP; Groll A; Beck IT
Dig Dis Sci; 1987 Apr; 32(4):377-87. PubMed ID: 3829880
[TBL] [Abstract][Full Text] [Related]
15. Crohn's disease activity: assessment by factor VIII coagulation proteins.
Zielen S; Bender SW; Kreuz W; Posselt HG; Solem E; Scharrer I
J Pediatr Gastroenterol Nutr; 1985 Oct; 4(5):730-4. PubMed ID: 3930684
[TBL] [Abstract][Full Text] [Related]
16. 111In-oxine-labelled white blood cells in the diagnosis and follow-up of Crohn's disease.
Becker W; Fischbach W; Jenett M; Reiners C; Börner W
Klin Wochenschr; 1986 Feb; 64(3):141-8. PubMed ID: 3081750
[TBL] [Abstract][Full Text] [Related]
17. Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease.
Folwaczny C; Wiebecke B; Loeschke K
Am J Gastroenterol; 1999 Jun; 94(6):1551-5. PubMed ID: 10364024
[TBL] [Abstract][Full Text] [Related]
18. Plasma levels of endothelin-1 in patients with Crohn's disease and ulcerative colitis.
Letizia C; Boirivant M; De Toma G; Cerci S; Subioli S; Scuro L; Ferrari P; Pallone F
Ital J Gastroenterol Hepatol; 1998 Jun; 30(3):266-9. PubMed ID: 9759593
[TBL] [Abstract][Full Text] [Related]
19. Oral butyrate for mildly to moderately active Crohn's disease.
Di Sabatino A; Morera R; Ciccocioppo R; Cazzola P; Gotti S; Tinozzi FP; Tinozzi S; Corazza GR
Aliment Pharmacol Ther; 2005 Nov; 22(9):789-94. PubMed ID: 16225487
[TBL] [Abstract][Full Text] [Related]
20. Individual fecal alpha 1-antitrypsin excretion reflects clinical activity in Crohn's disease but not in ulcerative colitis.
Becker K; Berger M; Niederau C; Frieling T
Hepatogastroenterology; 1999; 46(28):2309-14. PubMed ID: 10521988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
